<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472393</url>
  </required_header>
  <id_info>
    <org_study_id>USP.BONE</org_study_id>
    <nct_id>NCT01472393</nct_id>
  </id_info>
  <brief_title>Creatine on Bone Mass in Postmenopausal Women</brief_title>
  <official_title>A Randomized Controlled Trial: Effects of Creatine Supplementation on Bone Mass and Turnover and Muscle Function in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AlzChem AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Animal, in vitro and small-scale studies have suggested that creatine supplementation may
      augment bone mass. This clinical trial aims to investigate the effects of a 2-year creatine
      supplementation protocol on bone mass in postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density (BMD)</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone markers</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>will include CTX and P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>history of falls</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone microarchitecture</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle function</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lean mass</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory parameters</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Creatine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine supplementation</intervention_name>
    <description>The CR group will receive either 1g or 3g of Cr monohydrate (CreapureÂ®) per day throughout the trial. The dose of creatine will be formulated in a tablet.</description>
    <arm_group_label>Creatine supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dextrose (placebo)</intervention_name>
    <description>The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy postmenopausal women

          -  T-score at lumbar spine, or femoral neck or total femur of between -1SD and -2.5SD

        Exclusion Criteria:

          -  drugs or dietary supplements that may affect bone metabolism (e.g., bisphosphonates,
             AINEs, hormone replacement therapy, calcium, vitamin D, creatine supplementation)

          -  low BMI (&lt; 18.5 Kg/m2).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Gualano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa M Pereira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Gualano, PhD</last_name>
    <phone>551130913096</phone>
    <email>gualano@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sao Paulo - School of Medicine</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Madureira, PhD</last_name>
      <phone>5511 30617158</phone>
      <email>melisamadureira@usp.br</email>
    </contact>
    <investigator>
      <last_name>Bruno Gualano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa M' Pereira, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Gualano</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>creatine supplementation</keyword>
  <keyword>bone mass</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>muscle function</keyword>
  <keyword>bone markers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

